Status:

UNKNOWN

S-1 or Tegafur-Uracil in Treating Patients With Previously Treated Stage III or Stage IV Head and Neck Cancer

Lead Sponsor:

Yokohama City University

Conditions:

Head and Neck Cancer

Eligibility:

All Genders

20-75 years

Phase:

PHASE3

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as S-1 and tegafur-uracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving S...

Detailed Description

OBJECTIVES: * Compare the disease-free survival rate in patients with definitively treated stage III or IV squamous cell carcinoma of the head and neck treated with adjuvant chemotherapy comprising S...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Histologically or cytologically confirmed squamous cell carcinoma of the head and neck (SCCHN)
  • Stage III or IV disease
  • Primary tumor in the mesopharynx, hypopharynx, larynx (except T3 N0 tumors of the glottis), oral cavity, or maxillary sinus
  • Completed definitive treatment for SCCHN within the past 3 months, that included any of the following:
  • Surgery
  • Chemotherapy
  • Biologic therapy
  • Radiotherapy (e.g., radiotherapy in combination with chemotherapy or pre- or postoperative radiotherapy)
  • Any other treatment
  • No clinical evidence of locoregional tumors or distant metastasis within 3 months after the completion of definitive treatment
  • PATIENT CHARACTERISTICS:
  • ECOG performance status 0-1
  • WBC ≥ 3,500/mm\^3 AND ≤ 12,000/mm\^3
  • Neutrophil count ≥ 2,000/mm\^3
  • Platelet count ≥ 100,000/mm\^3
  • Hemoglobin ≥ 9 g/dL
  • AST and ALT \< 100 IU/L
  • Bilirubin \< 1.5 mg/dL
  • Creatinine \< 1.2 mg/dL
  • No uncontrolled cardiovascular disease
  • No interstitial pneumonia or pulmonary fibrosis
  • Must have sufficient oral intake
  • PRIOR CONCURRENT THERAPY:
  • See Disease Characteristics
  • No concurrent biologic therapy, radiotherapy, other chemotherapy, or any other therapy

Exclusion

    Key Trial Info

    Start Date :

    April 1 2006

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    Estimated Enrollment :

    500 Patients enrolled

    Trial Details

    Trial ID

    NCT00336947

    Start Date

    April 1 2006

    Last Update

    May 15 2013

    Active Locations (48)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 12 (48 locations)

    1

    Aichi Cancer Center

    Nagoya, Aichi-ken, Japan, 464-8681

    2

    Fujita Health University

    Toyoake, Aichi-ken, Japan, 470-11

    3

    Akita University Hospital

    Akita, Akita, Japan, 010-854

    4

    Tokyo Dental College Ichikawa General Hospital

    Ichikawa, Chiba, Japan, 272-8513